Drug Farm Completes First Closing of $55 Million Series D Financing to Advance Clinical and Preclinical Development Pipeline

Drug Farm Completes First Closing of $55 Million Series D Financing to Advance Clinical and Preclinical Development Pipeline

Drug Farm today announced the successful first closing of its $55 million Series D financing. The financing round was co-led by Shanghai Pudong Leading Area Investment Center and Shanghai Puxing Collaborative Private Equity Fund Partnership Enterprise, with participation from new investors Tukar Capital, Fuzhou Xinhe Fund, Shenzhen Luohu Donghai Chempartner Investment Fund, and Keyuan Pharma. Existing investors, including BioVeda China Fund (BVCF), YD Capital, Jiashan State VC, Detong Capital, Wedo Capital, and Biometas, also participated in the round.

The proceeds from the financing will support the continued advancement of Drug Farm's clinical and preclinical stage pipeline, accelerate global clinical development programs, strengthen regulatory activities across key markets, and further expand the company's research and development capabilities.

"The successful completion of this financing represents an important milestone in Drug Farm's mission to develop first-in-class drugs for the world. We are pleased to welcome our new investors while receiving continued support from our long-term shareholders, reflecting strong confidence in the company's scientific innovation, development strategy, and long-term vision. We believe this financing positions Drug Farm to create significant value for patients, partners, and shareholders in the years ahead,” said Dr. Tian Xu, Founder and Chairman of Drug Farm.